Clinic
Sentara Princess Anne Hospital
Sentara Princess Anne Hospital was paid $37.50M by Medicaid between Jan 2018 and Dec 2024, across 277 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoSENTARA PRINCESS ANNE HOSPITAL
VIRGINIA BEACH, VA 23456
VIRGINIA BEACH, VA 23456
33aNPI1528028396assigned 03/25/2006
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$37.50M
24GClaims1,097,962
24DCodes billed277
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in Virginia
Rank by total paid#5 of 6
Median peer was paid$52.40M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,439 | $2.13M | |
| 2019 | 143,008 | $3.28M | |
| 2020 | 130,213 | $4.68M | |
| 2021 | 173,833 | $6.02M | |
| 2022 | 193,340 | $6.74M | |
| 2023 | 221,003 | $8.79M | |
| 2024incomplete | 142,126 | $5.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 44,048 | 36,523 | $6.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 33,024 | 26,818 | $5.32M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 13,162 | 9,570 | $3.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 17,709 | 14,663 | $3.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 9,358 | 8,008 | $1.78M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 35,544 | 9,322 | $1.74M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 10,270 | 9,064 | $1.56M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 8,136 | 6,851 | $1.41M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.4% | 9,698 | 2,517 | $1.29M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.0% | 3,025 | 2,654 | $755K |
| 59025 | Fetal non-stress test | 1.7% | 3,476 | 2,655 | $646K |
| G0378 | Hospital observation service, per hour | 1.5% | 2,613 | 1,890 | $561K |
265 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 15,587 | $544K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 21,090 | $489K |
| 97161 | 1.2% | 4,021 | $438K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,650 | $427K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,352 | $416K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,039 | $341K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 903 | $282K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,091 | $257K |
| 97162 | <1% | 2,385 | $240K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,310 | $235K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,146 | $228K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,435 | $218K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,781 | $195K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,308 | $186K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 340 | $185K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,249 | $175K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 45,088 | $173K |
| J3490 | Unclassified drugs | <1% | 149,568 | $168K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,283 | $166K |
| 59050 | <1% | 682 | $153K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 794 | $149K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,150 | $141K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,989 | $125K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,655 | $120K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,501 | $113K |
| 76830 | Ultrasound, transvaginal | <1% | 1,663 | $112K |
| 93971 | <1% | 1,241 | $104K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,378 | $103K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,095 | $103K |
| 0240U | <1% | 1,914 | $101K | |
| 93017 | <1% | 1,201 | $97K | |
| 97165 | <1% | 1,066 | $96K | |
| 76642 | <1% | 656 | $76K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 374 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,144 | $74K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 943 | $69K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,246 | $65K |
| 72141 | <1% | 304 | $65K | |
| 71250 | <1% | 869 | $57K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,053 | $49K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,410 | $47K |
| 64483 | <1% | 61 | $46K | |
| 97116 | <1% | 2,077 | $45K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 188 | $42K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,424 | $40K |
| 70491 | <1% | 203 | $39K | |
| 80047 | <1% | 11,039 | $37K | |
| 64493 | <1% | 45 | $33K | |
| 83880 | <1% | 4,132 | $32K | |
| 94060 | <1% | 572 | $31K | |
| 10060 | <1% | 230 | $31K | |
| 85379 | <1% | 6,122 | $31K | |
| 80076 | <1% | 14,940 | $30K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,988 | $29K |
| 80053 | Comprehensive metabolic panel | <1% | 4,935 | $26K |
| 76536 | <1% | 227 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,309 | $25K |
| 97016 | <1% | 785 | $24K | |
| 84484 | <1% | 16,356 | $24K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,005 | $21K |
| 76770 | <1% | 151 | $21K | |
| 94726 | <1% | 713 | $20K | |
| 97113 | <1% | 563 | $20K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,813 | $19K |
| 93970 | <1% | 159 | $19K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,530 | $19K |
| 94729 | <1% | 763 | $18K | |
| 70486 | <1% | 328 | $18K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,090 | $16K |
| 97166 | <1% | 112 | $16K | |
| 90715 | <1% | 817 | $15K | |
| 82962 | <1% | 13,949 | $15K | |
| 72110 | <1% | 1,095 | $14K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 111 | $14K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,252 | $14K |
| 73130 | <1% | 1,484 | $14K | |
| 73030 | <1% | 1,341 | $13K | |
| 85027 | <1% | 7,278 | $13K | |
| 73564 | <1% | 2,073 | $13K | |
| 73630 | <1% | 2,249 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 292 | $12K |
| 84703 | <1% | 10,019 | $12K | |
| 86850 | <1% | 2,697 | $12K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 727 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,764 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 751 | $10K |
| 29125 | <1% | 76 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,849 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,450 | $9K |
| 86900 | <1% | 3,978 | $9K | |
| 73610 | <1% | 1,826 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 99 | $9K |
| 93976 | <1% | 320 | $9K | |
| 85014 | <1% | 6,584 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 298 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,924 | $8K |
| 77065 | Tomosynthesis, mammo | <1% | 209 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,186 | $7K |
| 81025 | <1% | 12,374 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 620 | $7K |
| 64635 | <1% | 19 | $7K | |
| 81001 | <1% | 22,872 | $7K | |
| 20610 | <1% | 68 | $6K | |
| 96376 | <1% | 7,457 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,664 | $6K |
| 64494 | <1% | 18 | $6K | |
| 64495 | <1% | 17 | $6K | |
| 83605 | <1% | 4,746 | $6K | |
| 94799 | <1% | 1,992 | $6K | |
| 97163 | <1% | 27 | $6K | |
| 73502 | <1% | 545 | $5K | |
| 87040 | <1% | 1,731 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,598 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,286 | $5K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,808 | $5K |
| 97750 | <1% | 273 | $5K | |
| 74018 | <1% | 434 | $4K | |
| 27096 | <1% | 15 | $4K | |
| 85610 | <1% | 4,310 | $4K | |
| 64636 | <1% | 20 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,184 | $4K |
| 83690 | <1% | 12,417 | $4K | |
| 81003 | <1% | 12,918 | $4K | |
| 85018 | <1% | 1,780 | $4K | |
| 73110 | <1% | 534 | $3K | |
| 82565 | <1% | 2,195 | $3K | |
| C1729 | Catheter, drainage | <1% | 622 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,746 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,480 | $3K |
| 83735 | <1% | 3,998 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,553 | $3K |
| 77080 | <1% | 46 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 20 | $3K |
| 76942 | <1% | 28 | $3K | |
| 84702 | <1% | 3,143 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 993 | $3K |
| 80061 | Lipid panel | <1% | 1,094 | $3K |
| 64450 | <1% | 14 | $2K | |
| 97802 | <1% | 16 | $2K | |
| 86901 | <1% | 3,979 | $2K | |
| 71271 | <1% | 27 | $2K | |
| 12011 | <1% | 13 | $2K | |
| 85730 | <1% | 1,441 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,005 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,806 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,948 | $2K |
| 90686 | <1% | 198 | $2K | |
| 87210 | <1% | 6,208 | $2K | |
| 72100 | <1% | 111 | $2K | |
| 72050 | <1% | 83 | $2K | |
| 87631 | <1% | 55 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,922 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,863 | $1K |
| 87077 | <1% | 3,382 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,528 | $1K |
| 80143 | <1% | 191 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,549 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 371 | $1K |
| 88304 | <1% | 389 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,245 | $1K |
| 87428 | <1% | 1,900 | $1K | |
| 84145 | <1% | 213 | $1K | |
| 82077 | <1% | 3,318 | $966.69 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 27 | $964.05 |
| 76870 | <1% | 14 | $927.99 | |
| 82553 | <1% | 235 | $848.94 | |
| 87081 | <1% | 2,569 | $828.91 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,568 | $800.51 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,108 | $762.24 |
| 73140 | <1% | 197 | $751.78 | |
| G0008 | Administration of influenza virus vaccine | <1% | 672 | $730.47 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,334 | $693.06 |
| 94618 | <1% | 15 | $693.06 | |
| 87186 | <1% | 2,045 | $606.43 | |
| 73562 | <1% | 61 | $602.44 | |
| 73590 | <1% | 128 | $585.00 | |
| 82310 | <1% | 2,119 | $558.34 | |
| 80179 | <1% | 142 | $517.24 | |
| 82570 | <1% | 537 | $462.45 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 886 | $461.98 |
| 84439 | <1% | 78 | $441.33 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 166 | $401.95 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,845 | $396.87 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,079 | $372.09 |
| 51798 | <1% | 66 | $361.05 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 12 | $350.50 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,515 | $278.65 |
| 72072 | <1% | 13 | $274.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,118 | $273.78 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 181 | $258.18 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 882 | $200.18 |
| 84550 | <1% | 665 | $185.61 | |
| 73080 | <1% | 49 | $168.71 | |
| 83615 | <1% | 539 | $136.71 | |
| 82550 | <1% | 539 | $122.14 | |
| 84156 | <1% | 313 | $118.17 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 32 | $115.17 |
| 80164 | <1% | 17 | $111.60 | |
| 84100 | <1% | 296 | $100.06 | |
| 80069 | <1% | 41 | $88.97 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 81 | $73.54 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 137 | $63.30 |
| J1815 | Injection, insulin, per 5 units | <1% | 349 | $62.56 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,086 | $60.77 |
| 82607 | <1% | 16 | $49.29 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 56 | $45.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 634 | $42.88 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 138 | $42.25 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 56 | $37.85 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 556 | $34.98 |
| 87070 | <1% | 220 | $33.66 | |
| 87205 | <1% | 389 | $32.95 | |
| 90694 | <1% | 15 | $25.17 | |
| 82746 | <1% | 14 | $24.29 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,204 | $21.44 |
| 87807 | <1% | 44 | $17.34 | |
| 82803 | <1% | 43 | $14.61 | |
| 87340 | <1% | 12 | $13.14 | |
| 82330 | <1% | 112 | $12.98 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 112 | $11.97 |
| 85652 | <1% | 15 | $11.83 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 152 | $11.14 |
| 82272 | <1% | 63 | $10.99 | |
| 84132 | <1% | 97 | $8.75 | |
| 82043 | <1% | 14 | $8.72 | |
| 80320 | <1% | 24 | $8.13 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 71 | $7.73 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 81 | $6.37 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 58 | $2.60 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 83 | $1.82 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 70 | $1.71 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $1.50 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 81 | $0.31 |
| C1769 | Guide wire | 0% | 579 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 294 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 173 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 198 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 372 | $0.00 |
| 90688 | 0% | 51 | $0.00 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 27 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 106 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 50 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 44 | $0.00 |
| 99234 | 0% | 31 | $0.00 | |
| 73090 | 0% | 14 | $0.00 | |
| 74022 | 0% | 29 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 18 | $0.00 |
| 88342 | 0% | 28 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 152 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 359 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 46 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 279 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 77 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 151 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 35 | $0.00 |
| 90756 | 0% | 25 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 72 | $0.00 |
| 90653 | 0% | 59 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 93 | $0.00 |
| 82009 | 0% | 15 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 290 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
Parent organizationSENTARA HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Norfolk, VA | $79.69M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.